ArticleBlood cancer journal2024

Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma.

Rajshekhar Chakraborty et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.